Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.
Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin. Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different. Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P). as well as of those of seven other tuberculous patients. This last finding may be related to time of testing and/or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte.
D000328:Adult; D000368:Aged; D006801:Humans; D007111:Immunity, Cellular; D007128:Immunoglobulin Fragments; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008875:Middle Aged; D011507:Proteinuria / Q000139:chemically induced*; D012293:Rifampin / Q000009:adverse effects*; D012882:Skin Tests; D014376:Tuberculosis / Q000188:drug therapy* / Q000276:immunology
D007128:Immunoglobulin Fragments; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D012293:Rifampin